Algin - Evista (Raloxifene) Interaction
Herbal: Algin
Also Known As: Alginate, Alginate de Calcium, Alginate de Magnésium, Alginate de Potassium, Alginate de Sodium, Alginate Salt Alginates, Alginato, Alginato de Calcio, Alginato de Magnesio, Alginato de Potasio, Alginato de Sodio, Algine, Calcium Alginate, Magnesium Alginate, Potassium
Drug: Raloxifene
Brand names:
Evista
Medical Content Editor Dr. Brian Staiger, PharmD
Last updated
Jul 22, 2023
Interaction Details
Raloxifene is classified as belonging to the following category: Oral Drugs
Theoretically, algin can alter the absorption of oral drugs. Laboratory research shows that algin, when consumed as part of the diet or used as a thickening agent in infant formula, reduces the absorption of certain minerals. Also, algin has been used as a tablet binder and disintegrant to enhance drug bioavailability. To avoid changes in absorption, take algin 30-60 minutes after oral medications.
Interaction Rating
Likelihood of Occurrence
PossibleInteraction has been documented in animal or in lab research, or the interaction has been documented in humans but is limited to case reports or conflicting clinical research exists
References
- Harmuth-Hoene, A. E. and Schelenz, R. Effect of dietary fiber on mineral absorption in growing rats. J Nutr 1980;110(9):1774-1784.
- Bosscher D, Van Caillie-Bertrand M, Deelstra H. Effect of thickening agents, based on soluble dietary fiber, on the availability of calcium, iron, and zinc from infant formulas. Nutrition. 2001;17(7-8):614-8.
- Beneke CE, Viljoen AM, Hamman JH. Polymeric plant-derived excipients in drug delivery. Molecules. 2009;14(7):2602-20.
Algin Overview
Raloxifene Overview
-
Raloxifene is used to prevent and treat osteoporosis (condition in which the bones become thin and weak and break easily) in postmenopausal (women who have experienced a change of life; end of menstrual periods) women. Raloxifene is also used to decrease the risk of developing invasive breast cancer (breast cancer that has spread outside of the milk ducts or lobules into the surrounding breast tissue) in postmenopausal women who are at high risk of developing this type of cancer or who have osteoporosis. Raloxifene cannot be used to treat invasive breast cancer or to prevent invasive breast cancer from coming back in women who have already had the condition. Raloxifene also cannot be used to decrease the risk of developing noninvasive breast cancer. Raloxifene should not be used in women who have not yet experienced menopause. Raloxifene is in a class of medications called selective estrogen receptor modulators (SERMs). Raloxifene prevents and treats osteoporosis by mimicking the effects of estrogen (a female hormone produced by the body) to increase the density (thickness) of bone. Raloxifene decreases the risk of developing invasive breast cancer by blocking the effects of estrogen on breast tissue. This may stop the development of tumors that need estrogen to grow.
Algin - More Interactions
Algin interacts with 1987 drugs
Interaction Rating Key
These severity listings are for informational use only. Never start, stop or otherwise change your therapy before speaking with your provider.
Major | The combined use of these agents is strongly discouraged as serious side effects or other negative outcomes could occur. |
Moderate | Use cautiously under the care of a healthcare professional or avoid this combination. A significant interaction or negative outcome could occur. |
Minor | Be aware that there is a chance of an interaction. Watch for warning signs of a potential interaction. |
Unknown | No interactions have been reported or no interaction data is currently available. |
Return to the main herbal interaction checker page
Parts of this content are provided by the Therapeutic Research Center, LLC.
DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.
© 2021 Therapeutic Research Center, LLC
Drug descriptions are provided by MedlinePlus.